TANG KEVIN 4

What Happened
Kevin Tang, a reported 10% owner of Boundless Bio (BOLD), made multiple open‑market purchases (transaction code P) totaling 107,463 shares between 2026-06-30 and 2026-07-02. The purchases break down as: 25,930 shares at a reported weighted‑average $2.54 ($65,862), 100 shares at $2.50 ($250), 71,612 shares at a weighted‑average $2.49 ($178,314), and 9,821 shares at a weighted‑average $2.49 ($24,454). Total cash outlay across these trades was about $268,880. Purchases are generally considered a bullish signal (as opposed to sales), though no motive is stated.

Key Details

• Transaction dates: 2026-06-30 (two lots), 2026-07-01, 2026-07-02. All are open‑market purchases (P).
• Reported per‑lot values: $65,862; $250; $178,314; $24,454. Total ≈ $268,880.
• Price disclosure: filing reports weighted‑average prices and notes purchases were executed in multiple transactions with price ranges reported in the footnotes (roughly $2.46–$2.60 across lots). More granular per‑trade pricing is available from the filer on request.
• Shares owned after transaction: not specified in the provided excerpt. The filing notes related entities beneficially own shares: TCP 605,296; TCPI 825,422; TCP III 605,294; TCP IV 605,296, and Mr. Tang has a pecuniary interest in those holdings.
• No indication in the provided information that the Form 4 was filed late.

Context

• Kevin Tang is reported as a 10% owner with beneficial interests through several Tang Capital entities—this is large‑owner/investor trading rather than routine employee compensation activity.
• These were straightforward open‑market purchases (not option exercises, gifts, or awards). Footnotes clarify weighted averages and price ranges and state the filer will provide per‑trade breakdowns on request.
• Retail investors often watch insider buys like this as one data point; it does not by itself prove future performance.